TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38917404

Group type: EXPERIMENTAL
Intervention: Outpatient high-dose methotrexate (HD-MTX) with glucarpidase 2000u
Number of subjects: 7
Study: 38917525

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily plus mesalamine 1 g three times daily for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mesalamine 1 g three times daily for 6 months
Number of subjects: 60
Study: 38917696

Group type: EXPERIMENTAL
Intervention: Kinesthetic and Visual Imagery Questionnaire-10 (KVIQ-10)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 38
Study: 38917793

Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 38918103

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster (5 × 10^10 viral particles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster (other dose levels)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38918235

Group type: EXPERIMENTAL
Intervention: Atoguanil™
Number of subjects: 0

Group type: COMPARATOR
Intervention: Malarone® (atovaquone-proguanil hydrochloride)
Number of subjects: 0
Study: 38918556

Group type: EXPERIMENTAL
Intervention: Stacking model for predicting axillary lymph node (ALN) response to neoadjuvant chemotherapy (NAC) using longitudinal MRI.
Number of subjects: 1153

Group type: COMPARATOR
Intervention: Radiologists' assessment of ALN response to NAC.
Number of subjects: 1153

Group type: EXPERIMENTAL
Intervention: Comparison of disease-free survival between high-risk and low-risk groups.
Number of subjects: 1153
Study: 38918590

Group type: EXPERIMENTAL
Intervention: Topical simvastatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical atorvastatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 38918630

Group type: EXPERIMENTAL
Intervention: Portable thermal ablation (TA) device
Number of subjects: 3124

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 3124

Group type: COMPARATOR
Intervention: Large loop excision of transformation zone (LLETZ)
Number of subjects: 3124
Study: 38918695

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 124
Study: 38918780

Group type: EXPERIMENTAL
Intervention: TB/TBI treatment
Number of subjects: 11
Study: 38918806

Group type: EXPERIMENTAL
Intervention: Whole-body 18FDG-PET/CT scans in patients with microbiologically confirmed spinal tuberculosis
Number of subjects: 0
Study: 38918869

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques with 12 weeks of direct acting antiviral (DAA) treatment
Number of subjects: 20
Study: 38918871

Group type: EXPERIMENTAL
Intervention: Abatacept (subcutaneous)
Number of subjects: 219
Study: 38918903

Group type: EXPERIMENTAL
Intervention: Endoscopic transsphenoidal surgery
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: STOP-Bang score ≥ 3
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Biochemical acromegaly remission
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Changes in REI
Number of subjects: 35
Study: 38919489

Group type: EXPERIMENTAL
Intervention: T2DM patients with comorbid conditions
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: T2DM patients with one comorbid condition
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: T2DM patients with two comorbid conditions
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: T2DM patients with three comorbid conditions
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: T2DM patients with four or more comorbid conditions
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: Comorbidity burden in relation to diabetes duration
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: Comorbidity burden by age group
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: Comorbidity prevalence by gender
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: Most common comorbid conditions in T2DM patients
Number of subjects: 25454

Group type: EXPERIMENTAL
Intervention: Co-prevalence of comorbid conditions
Number of subjects: 25454
Study: 38919520

Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure (ICP) monitoring using distortion product otoacoustic emissions (DPOAE)
Number of subjects: 125
Study: 38919522

Group type: EXPERIMENTAL
Intervention: TP-based induction chemotherapy followed by radiotherapy (IC+RT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: TL followed by postoperative radiotherapy (TL+PORT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: TL followed by postoperative radiochemotherapy (TL+PORCT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: cisplatin-based concurrent radiochemotherapy (CRT)
Number of subjects: 52
Study: 38919799

Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Water Aerobics (WA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined intervention (WA and MCT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 38919826

Group type: EXPERIMENTAL
Intervention: Spartalizumab (PDR001) 300 mg intravenous every three weeks until disease progression or unacceptable toxicity
Number of subjects: 44
Study: 38919921

Group type: EXPERIMENTAL
Intervention: START NOW Adapted
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80
Study: 38920025

Group type: EXPERIMENTAL
Intervention: Patients with CAA
Number of subjects: 207

Group type: COMPARATOR
Intervention: Hypertensive arteriopathy
Number of subjects: 207
Study: 38920297

Group type: EXPERIMENTAL
Intervention: Remdesivir plus standard of care (SOC)
Number of subjects: 3399

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 3399
Study: 38920407

Group type: EXPERIMENTAL
Intervention: Adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle)
Number of subjects: 18
Study: 38920618

Group type: EXPERIMENTAL
Intervention: Lung-Protective Mechanical Ventilation (LPMV) protocol
Number of subjects: 693

Group type: COMPARATOR
Intervention: Standard care (non-LPMV)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: LPMV protocol
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Adherence to LPMV strategies
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Adherence to PIP, DP, and PEEP/F io2 combinations
Number of subjects: 693
Study: 38921304

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (dancing and resistance exercises, nutritional education)
Number of subjects: 12
Study: 38921720

Group type: EXPERIMENTAL
Intervention: Telenursing intervention for PICC management (experimental group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Outpatient dressing for PICC at the hospital (control group)
Number of subjects: 72
Study: 38921800

Group type: EXPERIMENTAL
Intervention: Nirsevimab (50 mg for <5 kg, 100 mg for ≥5 kg, 200 mg for second season)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palivizumab (5× once-monthly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nirsevimab (200 mg for re-randomized first-season palivizumab recipients)
Number of subjects: 0
Study: 38922218

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (6 sessions)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham stimulation (6 sessions)
Number of subjects: 13
Study: 38922307

Group type: EXPERIMENTAL
Intervention: sacituzumab govitecan + pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: pembrolizumab (± capecitabine)
Number of subjects: 0
Study: 38922306

Group type: EXPERIMENTAL
Intervention: Parent-led, home-based early intervention for motor development, engaging in multidomain stimulation activities five days a week for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38922428

Group type: EXPERIMENTAL
Intervention: Freestyle Libre pro IQ sensor (blinded continuous glucose monitoring) for 14 days
Number of subjects: 29
Study: 38922435

Group type: EXPERIMENTAL
Intervention: Telerehabilitation home program (TRP) in addition to pharmaceutical treatment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Pharmaceutical treatment (Control)
Number of subjects: 400
Study: 38922484

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks
Number of subjects: 0
Study: 38922488

Group type: EXPERIMENTAL
Intervention: Updated risk factor time path equations
Number of subjects: 28608

Group type: COMPARATOR
Intervention: Original risk factor time path equations
Number of subjects: 28608
Study: 38922520

Group type: EXPERIMENTAL
Intervention: DKP/TRAM 25/75 mg every 8 h (n=211)
Number of subjects: 538
Study: 38922577

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) combined with high-intensity interval training (HIIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 38922618

Group type: EXPERIMENTAL
Intervention: Chat-based cessation support delivered by a live counselor via a mobile instant messaging app for 3 months from baseline.
Number of subjects: 624
Study: 38922632

Group type: EXPERIMENTAL
Intervention: Routine functional testing
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1706
Study: 38922689

Group type: EXPERIMENTAL
Intervention: Twice Weekly Hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrice Weekly Hemodialysis
Number of subjects: 0
Study: 38922906

Group type: EXPERIMENTAL
Intervention: 800 mg/day DHA supplementation during pregnancy (PGO-800)
Number of subjects: 169

Group type: COMPARATOR
Intervention: 200 mg/day DHA supplementation during pregnancy (PGO-200)
Number of subjects: 169
Study: 38922990

Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant FIX Fc fusion protein (rFIXFc), n=11
Number of subjects: 33

Group type: COMPARATOR
Intervention: On demand (OD) treatment with rFIXFc, n=22
Number of subjects: 33
Study: 38923102

Group type: EXPERIMENTAL
Intervention: Computerized intraosseous anesthesia (CIOA) using QuickSleeper 5
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (IANB)
Number of subjects: 88
Study: 38923140

Group type: EXPERIMENTAL
Intervention: Evidence-based guideline-directed medical therapy (GDMT)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Comorbidity treatment
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Sequence of treatment introduction and up-titration
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: GDMT implementation
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Causes of GDMT underuse
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Cumulative rate of cardiovascular events
Number of subjects: 2500
Study: 38923439

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin prophylaxis from <16 weeks until 36 weeks for high-risk women
Number of subjects: 48725

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin prophylaxis for high-risk women
Number of subjects: 48725

Group type: COMPARATOR
Intervention: Screen-and-prevent strategy for preterm preeclampsia
Number of subjects: 48725
Study: 38923527

Group type: EXPERIMENTAL
Intervention: Online matching-task (MT) paradigm
Number of subjects: 40
Study: 38923743

Group type: EXPERIMENTAL
Intervention: Younger individuals (20-39 years)
Number of subjects: 9848

Group type: EXPERIMENTAL
Intervention: Older individuals (≥40 years)
Number of subjects: 9848
Study: 38923871

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg QD
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg QD)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Upadacitinib and ABBV-599 high dose
Number of subjects: 341
Study: 38923910

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy (TIS+Chemo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (Chemo)
Number of subjects: 0
Study: 38923965

Group type: EXPERIMENTAL
Intervention: 0.01% atropine administered twice daily with optical defocus (DIMS lenses)
Number of subjects: 112

Group type: COMPARATOR
Intervention: 0.01% atropine administered twice daily (single vision lenses)
Number of subjects: 112
Study: 38924038

Group type: EXPERIMENTAL
Intervention: Telehealth intervention (four remote educational sessions)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Standard educational approach (four in-person sessions)
Number of subjects: 384
Study: 38924124

Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 89

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 89
Study: 38924169

Group type: EXPERIMENTAL
Intervention: Integrated Pulmonary Index enabled
Number of subjects: 0

Group type: COMPARATOR
Intervention: Integrated Pulmonary Index disabled
Number of subjects: 0
Study: 38924429

Group type: EXPERIMENTAL
Intervention: AZD3152 (600 mg intramuscular injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD3152 (prophylactic administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD3152
Number of subjects: 0
Study: 38924456

Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Number of subjects: 1
Study: 38924481

Group type: EXPERIMENTAL
Intervention: Virtual environment for CVD prevention education
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Virtual environment features
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Avatar customization options
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CVD risk factors
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Concerns regarding comorbid conditions
Number of subjects: 25
Study: 38924724

Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg BID
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg QD
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755
Study: 38924731

Group type: EXPERIMENTAL
Intervention: Higher-exposure dupilumab regimen
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lower-exposure dupilumab regimen
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 38924732

Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg subcutaneous every 4 weeks)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 38924756

Group type: EXPERIMENTAL
Intervention: Amivantamab-lazertinib
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Amivantamab-lazertinib vs. Osimertinib
Number of subjects: 1074
Study: 38924779

Group type: EXPERIMENTAL
Intervention: Video recording of MDC visit
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal after-visit summary (treatment as usual)
Number of subjects: 24
Study: 38924855

Group type: EXPERIMENTAL
Intervention: Induction systemic therapy followed by complete local treatment
Number of subjects: 215

Group type: COMPARATOR
Intervention: RECIST1.1
Number of subjects: 215
Study: 38924976

Group type: EXPERIMENTAL
Intervention: Pillow mannequin intervention group (n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 61
Study: 38925110

Group type: EXPERIMENTAL
Intervention: ECoG high gamma signals during speech
Number of subjects: 0
Study: 38925354

Group type: EXPERIMENTAL
Intervention: BEP supplementation (two 75-g sachets per day)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: BEP supplementation + Azithromycin (20 mg/kg at 42 days)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Control (standard-of-care counseling on exclusive breastfeeding, nutrition, infant immunization, and health promotion plus iron-folate supplementation)
Number of subjects: 957
Study: 38925586

Group type: EXPERIMENTAL
Intervention: 3 mg PEG-rhG-CSF
Number of subjects: 122

Group type: COMPARATOR
Intervention: 6 mg PEG-rhG-CSF
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 3 mg PEG-rhG-CSF (BW ≤ 60 kg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 6 mg PEG-rhG-CSF (BW ≤ 60 kg)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 3 mg PEG-rhG-CSF (BW > 60 kg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 6 mg PEG-rhG-CSF (BW > 60 kg)
Number of subjects: 122
Study: 38925684

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) recordings (24-hour, supine, standing and exercise stress test)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) monitoring
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cognitive function, cardiorespiratory fitness, cardiovascular health, balance and strength assessments
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessments of exhaustion, mood and tension
Number of subjects: 153
Study: 38925688

Group type: EXPERIMENTAL
Intervention: Stable remission (BMI≥18.5 kg/m²)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Unstable remission (BMI<18.5 kg/m²)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Healthy controls (n=100)
Number of subjects: 125
Study: 38925694

Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells (UC-MSCs) treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MSCs-short group (UC-MSCs)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MSCs-prolonged group (UC-MSCs)
Number of subjects: 150
Study: 38925705

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme including exercise training, nutritional optimisation, and psychological support.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme (exercise training with a certified kinesiologist, nutritional optimisation with a registered dietician, psychological support with a nurse specialist).
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-intensity interval training on a cycle ergometer as part of the exercise training programme.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-transplantation outcomes will be recorded.
Number of subjects: 25
Study: 38925712

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PENG block with 18 mL of 0.5% ropivacaine mixed with 2 mL of a contrast agent
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PENG block
Number of subjects: 10
Study: 38925731

Group type: EXPERIMENTAL
Intervention: Sexual and reproductive health services
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 1743
Study: 38925803

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily on days 1-3, followed by 0.5 mg daily thereafter)
Number of subjects: 8343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8343

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 8343
Study: 38925869

Group type: EXPERIMENTAL
Intervention: High-dose allogeneic disc progenitor cells
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose cells
Number of subjects: 60
Study: 38926066

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Abiraterone Acetate and Prednisone
Number of subjects: 103
Study: 38926068

Group type: EXPERIMENTAL
Intervention: 27.476 IU YF vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 10.447 IU YF vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 3.013 IU YF vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 587 IU YF vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 158 IU YF vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 31 IU YF vaccine
Number of subjects: 318
Study: 38926142

Group type: EXPERIMENTAL
Intervention: exergame and acceptance and commitment therapy (e-ACT) programme
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy (ACT) only
Number of subjects: 126

Group type: COMPARATOR
Intervention: treatment-as-usual (TAU)
Number of subjects: 126
Study: 38926143

Group type: EXPERIMENTAL
Intervention: Adapted Dementia Care Management (DeCM) delivered by qualified dementia care managers for 6 months.
Number of subjects: 90
Study: 38926148

Group type: EXPERIMENTAL
Intervention: Norepinephrine weaning guided by the Hypotension Prediction Index (HPI) with MAP>65 mmHg and HPI<80
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group with norepinephrine weaning based solely on MAP>65 mm Hg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Norepinephrine weaning guided by the HPI
Number of subjects: 142
Study: 38926162

Group type: EXPERIMENTAL
Intervention: CLDN18.2-targeted nanobody, PMD22, labeled with gallium-68
Number of subjects: 0
Study: 38926266

Group type: EXPERIMENTAL
Intervention: Mavacamten 15 mg plus activated charcoal 50 g administered 2 h after mavacamten dosing
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mavacamten 15 mg plus activated charcoal 50 g administered 6 h after mavacamten dosing
Number of subjects: 45

Group type: COMPARATOR
Intervention: Mavacamten 15 mg alone
Number of subjects: 45
Study: 38926682

Group type: EXPERIMENTAL
Intervention: HCLD +  (n=287)
Number of subjects: 345

Group type: COMPARATOR
Intervention: HCLD- (n=58)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: HCLD +  (n=116 positive for SP)
Number of subjects: 345

Group type: COMPARATOR
Intervention: HCLD- (n=12 positive for SP)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: HCLD + 
Number of subjects: 345
Study: 38926693

Group type: EXPERIMENTAL
Intervention: PI*SS genotype
Number of subjects: 1007
Study: 38926732

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Th1 cell polarization
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: LCN2 and KDM5D genes
Number of subjects: 63
Study: 38926739

Group type: EXPERIMENTAL
Intervention: Adappt application (positive psychology and mindfulness-based app)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Adappt application
Number of subjects: 212